Telix Pharmaceuticals (TLPPF) Current Leases (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Current Leases for 4 consecutive years, with $59.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Leases changed N/A year-over-year to $59.6 million in Q2 2026; TTM through Jun 2026 was $59.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $56.5 million, down 64.76% from the prior year.
• Current Leases was $59.6 million for Q2 2026 at Telix Pharmaceuticals, up from $56.5 million in the prior quarter.
• Over five years, Current Leases peaked at $59.6 million in Q2 2026 and troughed at $5.0 million in Q4 2023.
• A 4-year average of $31.6 million and a median of $30.9 million in 2024 frame the typical range for Current Leases.
• Across the five-year window, Current Leases advanced 6.53% in 2024 and soared 961.9% in 2025, its largest moves.
• Over 4 years, Current Leases stood at $5.0 million in 2023, then increased by 6.53% to $5.3 million in 2024, then soared by 961.9% to $56.5 million in 2025, then grew by 5.35% to $59.6 million in 2026.
• The last three Current Leases figures came in at $59.6 million (Q2 2026), $56.5 million (Q4 2025), and $5.3 million (Q4 2024), per Business Quant data.